Catumaxomab for Malignant Ascites Associated With Gastric Cancer

Share this content:
Trifunctional antibodies such as catumaxomab may have a significant impact in treating these malignancies.
Trifunctional antibodies such as catumaxomab may have a significant impact in treating these malignancies.

Monoclonal antibodies (mAbs) are a growing class of medications used to treat a multitude of disease states, ranging from autoimmune diseases to cancer. There are over 40 mAbs marketed, with almost $100 billion worth of sales in the world.1 Although mAbs are a technical and clinical breakthrough, their utility is limited by the inability to target more than 1 cell mediator or pathway at the same time. This can lead to inefficient killing of cancer cells and the development of resistance.

In attempts to improve these inefficiencies, a new subtype of mAbs—trifunctional antibodies—are increasingly being studied in the development pipeline of several pharmaceutical companies. Catumaxomab is 1 of the earliest trifunctional antibodies developed for use in patients with malignant ascites.2

The binding arms of catumaxomab are unique in that each of the 2 arms binds 2 different targets. Traditionally, each arm (fragment antigen binding [Fab]) would bind the same target while the fragment crystallizable (Fc) region would interact with the cell surface receptor and/or the complement system.

With catumaxomab, 1 of the Fab arms binds epithelial cell adhesion molecule (EpCAM), which is a glycoprotein expressed on the surface of some types of cancer cells.3 The second Fab arm binds to cluster of differentiation 3 (CD3) on T cells, which helps activate the body's immune response against cancer. The Fc portion of the antibody binds to macrophages or natural killer cells, which help coordinate the attack on the tumor cells. The structure of catumaxomab is therefore a unique opportunity, bringing 3 different cell types together to make anticancer treatment more efficient and efficacious.

Malignancy is the underlying cause of ascites in up to 10% of all patients.4 The cancers most commonly associated with malignant ascites include ovarian, breast, gastric, and colorectal.5 Malignancy-related ascites is typically difficult to manage, with limited treatment options including diuretics and repeated large volume paracenteses, which can have a significant impact on a patient's quality of life.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters